Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

2.3K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Actuarial Approach01:20

Actuarial Approach

336
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
336
Preventive Healthcare Services01:30

Preventive Healthcare Services

2.3K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.3K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

292
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
292
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

4.4K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AABB survey on directed blood donation practices.

Transfusion·2026
Same author

Prevalence of Futility Protocols for Severely Bleeding Trauma Patients: A Survey from the Association for the Advancement of Blood & Biotherapies (AABB).

Journal of clinical medicine·2026
Same author

Implementation of Viscoelastic Testing at the Point of Care: Practical Pearls for Clinical Integration.

Clinics in laboratory medicine·2025
Same author

How we implement a prehospital transfusion program.

Transfusion·2025
Same author

Contemporary prehospital Emergency Medical Services in the United States: An overview and considerations for the Transfusion Medicine Community.

Transfusion·2025
Same author

Steps Forward to a Fair and Inclusive Blood Supply.

Clinics in laboratory medicine·2024

Related Experiment Video

Updated: Feb 28, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K

Implementation of the Individual Risk Assessment and Changes to Deferral Periods Since 2020.

Todd Straus1, Daniela Hermelin2, Emily Coberly3

  • 1Community Blood Center Inc, 4406 West Spencer Street, Appleton, WI 54914, USA.

Clinics in Laboratory Medicine
|February 25, 2026
PubMed
Summary
This summary is machine-generated.

Blood donor deferral management evolved significantly since 2020, notably with the adoption of individual risk assessment for HIV prevention. This shift presented unique challenges for blood centers in ensuring blood supply safety.

Keywords:
Blood safetyBlood safety guidanceDonor deferral periodsDonor eligibilityDonor healthGeographic travel deferralsRisk assessmentTransfusion-transmitted HIV

More Related Videos

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.8K
Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
15:00

Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies

Published on: February 3, 2023

3.2K

Related Experiment Videos

Last Updated: Feb 28, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.8K
Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
15:00

Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies

Published on: February 3, 2023

3.2K

Area of Science:

  • Transfusion Medicine
  • Public Health
  • Infectious Disease Prevention

Background:

  • Blood donor deferral is crucial for maintaining the safety of the blood supply.
  • Recent years have seen significant regulatory changes impacting blood donation eligibility.
  • The transition to new deferral strategies addresses evolving public health challenges.

Purpose of the Study:

  • To discuss key changes in regulated blood donor deferrals since 2020.
  • To examine the implementation of the individual risk assessment model for HIV risk mitigation.
  • To explore how blood centers adapted to these changes.

Main Methods:

  • Review of regulatory changes in blood donor deferrals.
  • Analysis of the implementation process for the individual risk assessment model.
  • Case study or discussion of blood center approaches.

Main Results:

  • The shift to individual risk assessment for HIV risk mitigation is a major change.
  • Implementation of this new model presented distinct challenges for blood centers.
  • Various blood centers adopted different strategies to manage deferral changes.

Conclusions:

  • Adapting blood donor deferral policies is essential for blood supply safety.
  • The individual risk assessment model represents a significant advancement in HIV risk mitigation.
  • Blood centers successfully navigated implementation challenges, ensuring continued safe blood donation.